Home » Stocks » AIH

Aesthetic Medical International Holdings Group Ltd. (AIH)

Stock Price: $5.08 USD 0.08 (1.60%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 118.06M
Revenue (ttm) 124.15M
Net Income (ttm) 19.76M
Shares Out 70.84M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE 13.18
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $5.08
Previous Close $5.00
Change ($) 0.08
Change (%) 1.60%
Day's Open 5.03
Day's Range 4.90 - 5.19
Day's Volume 100,015
52-Week Range 3.94 - 10.28

News

Hide News
GlobeNewsWire - 2 weeks ago

Shenzhen, China, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical servic...

Seeking Alpha - 1 month ago

Aesthetic Medical International's (AIH) CEO Pengwu Zhou on Q3 2020 Results - Earnings Call Transcript

Benzinga - 1 month ago

Shares of Aesthetic Medical Intl (NASDAQ:AIH) moved higher by 3.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share came in at $(0.04) down fro...

About AIH

Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistr... [Read more...]

Industry
Medical Care Facilities
IPO Date
Oct 25, 2019
CEO
Dr. Pengwu Zhou
Employees
1,550
Stock Exchange
NASDAQ
Ticker Symbol
AIH
Full Company Profile

Financial Performance

Financial numbers in millions CNY.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for AIH stock is "Strong Buy" and the 12-month stock price forecast is 7.97.

Price Target
$7.97
Analyst Consensus: Strong Buy